Skip to main content

Table 3 Patient characteristics at baseline

From: The effect of dosing strategies on the therapeutic efficacy of artesunate-amodiaquine for uncomplicated malaria: a meta-analysis of individual patient data

Variable

Asia

Africa

South America a

Overall

N

434 (4.77%)

8635 (94.83%)

37 (0.41%)

9106

Study period

2005-2009

1999-2012

2000-2004

1999-2012

Gender

    

Female

38.7% [168/434]

47.0% [4,060/8,635]

18.9% [7/37]

46.5% [4,235/9,106]

Age

    

Median age [IQR, range] in years

17 [8-28,0.6-80]

3 [1.7-5,0-80]

20 [16-25,8-58]

3 [1.8-6, 0-80]

<1 y

0.2% [1/434]

9.1% [782/8,635]

0.0% [0/37]

8.6% [783/9,106]

1 to <5 y

7.8% [34/434]

65.1% [5,619/8,635]

0% [0/37]

62.1% [5,653/9,106]

5 to <12 y

25.3% [110/434]

16.5% [1,421/8,635]

10.8% [4/37]

16.9% [1,535/9,106]

≥12 y

66.6% [289/434]

9.4% [813/8,635]

89.2% [33/37]

12.5% [1,135/9,106]

Treatment supervision b

    

Full

67.3% [292/434]

95.1% [8,212/8,635]

100.0% [37/37]

93.8% [8,541/9,106]

Partial

32.7% [142/434]

4.9% [423/8,635]

0.0% [0/37]

6.2% [565/9,106]

Drug formulation

    

Fixed dose combination (FDC)

78.6% [341/434]

44.0% [3,797/8,635]

0.0% [0/37]

45.4% [4,138/9,106]

Co-blistered non-fixed dose combination (co-blistered NFDC)

0.0% [0/434]

14.6% [1,257/8,635]

0.0% [0/37]

13.8% [1,257/9,106]

Loose non-fixed dose combination: target dose 25 mg/kg (loose NFDC-25)

0.0% [0/434]

15.0% [1,293/8,635]

0.0% [0/37]

14.2% [1,293/9,106]

Loose non-fixed dose combination: target dose 30 mg/kg (loose NFDC-30)

21.4% [93/434]

26.5% [2,288/8,635]

100.0% [37/37]

26.6% [2,418/9,106]

Enrolment clinical variables

    

Geometric mean parasitemia [95% CI] in parasites/μl

8,504 [7,409-9,761]

19,508 [18,944-20,089]

80 [55-116]

18,338 [17,801-18,891]

Median weight [IQR, range] in kg

40 [20-50,7-72]

12 [10-17, 5-104]

59 [47-65,24-80]

12.7 [10-18, 5-104]

Underweight for agec

37.1% [13/35]

20.6% [1,248/5,821]

-

20.7% [1,297/6,269]

Anemic (hb < 10 g/dl)d

34.3% [149/434]

59% [3,754/5,821]

13.5% [5/37]

56.6% [3,908/6,906]

Gametocytes presencee

39.4% [56/142]

10.0% [462/5,821]

24.3% [9/37]

11.0% [527/4,796]

Fever (temp > 37.5 °C)

77.7% [227/292]

66.4% [5,769/5,821]

16.2% [6/37]

68.5% [6,002/8,766]

Hemoglobin [mean ± SD] in g/dl

10.9 ± 2.29

9.5 ± 2.06

12.06 ± 1.93

9.6 ± 2.11

  1. aSingle study from Columbia.
  2. bTreatment supervision: The treatment was fully supervised if each dose of the three-day regimen was administered by a nurse/or any other medical staff. The treatment was partially supervised if only the dose on the first day was administered by medical staff, the dose on day 2 and day 3 being self-administered by the patients or the parents/guardians.
  3. cDefined using a weight-for-age score (WAZ) < -2 in children <5 years of age. WAZ scores outside the range (-6.6) were treated as outliers.
  4. dAsia v Africa (P = 0.005), Asia v South America (P = 0.438) and Africa v South America (P = 0.042).
  5. eAsia v Africa (P < 0.001), Asia v South America (P = 0.236) and Africa v South America (P = 0.308).
Back to article page

BMC Medicine

ISSN: 1741-7015

Contact us